Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Stay updated on the latest potential FDA drug approvals in 2025, including an expanded label for Ozempic and new, nonopioid painkillers.

British drug maker GSK plc (GSK, GSK.L) announced Friday that the US Food and Drug Administration has accepted for review the ...

Challenge trials help researchers study immune responses. Skeptics still doubt the approach is worth the risks ...

Intravenous BCG vaccine with a built-in kill-switch was found to be at least as effective as regular tuberculosis vaccine in ...

Germany's biologics market, the largest in Europe, is expected to grow at a 3.8% CAGR from 2025 to 2035. AI is driving this growth by enhancing R&D, optimizing drug design, and identifying novel ...

Everything you need to know about getting a Covid-19 vaccination ... there are vaccination updates in your state: The Plan Your Vaccine page will be updated as new information is released from ...

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...